مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

اين يمكنك التبليغ عن الاحداث الجانية للأدوية واللقاحات

 
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
 

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
 
How to report

You can send the case reports using the following tools:
 
  1. For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
 
  1. The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones
 
  1. Scan the QR Code by pressing the link
  2. Click the three dots in the top-right corner
  3. Choose Install app
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app
 
How to Download on Apple IOS Phones
 
  1. Scan the QR Code by pressing the link
  2. Click on the share button
  3. Add VigiMobile to the home screen
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows
  1. Press on the link
  2. Install from the Browser menu
  3. VigiMobile e-Form/e-Reporting e-Form is now installed 
 
Scan QR Codes to Report:
  1. ADRs Following Medication Use
  1. AEFIs Following Vaccine Use
Or use the following link: LNPVP: e-Reporting eForm Or use the following link: LNPVP: VigiMobile eForm
 
  1. Direct Contact with the Lebanese National Pharmacovigilance Program:
You may contact the Lebanese National Pharmacovigilance Program through:
  • Email Address:
  • Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254   
 
  1.  For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.
 
As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-
    5
    ...
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
J07AH MENFIVE G Meningococcal (serogroups A, C, Y, W, X) Polysaccharide conjugate vaccine - Injectable freeze dried powder + diluent 3,527,587 L.L
J02AX05 MYCAMINE B Micafungin (sodium) - 50mg 50mg Injectable lyophilised powder for solution 13,170,341 L.L
J02AX05 MEGMENTO G Micafungin (sodium) - 50mg 50mg Injectable powder for solution 9,530,364 L.L
J02AX05 MEGMENTO G Micafungin (sodium) - 100mg 100mg Injectable powder for solution 17,158,569 L.L
J02AC01 MYXEN G Fluconazole - 50mg/5ml 50mg/5ml Granules for suspension 793,507 L.L
J02AC01 MYXEN G Fluconazole - 50mg 50mg Tablet 755,112 L.L
J02AC01 MYXEN G Fluconazole - 150mg 150mg Tablet 255,970 L.L
J01XX01 MONUROL B Fosfomycine (trométamol) - 3g 3g Granules for solution 571,133 L.L
J01RA MEDSPIRAGYL G Metronidazole - 125mg, Spiramycin - 750,000IU Tablet, scored 474,824 L.L
J01MA14 MOFLOXINE G Moxifloxacin (HCl) - 400mg/250ml 400mg/250ml Injectable solution 1,638,144 L.L
J01MA12 MATADOR G Levofloxacin - 500mg 500mg Tablet, film coated 787,492 L.L
J01MA12 MATADOR G Levofloxacin - 750mg 750mg Tablet, film coated 1,126,140 L.L
J01GB06 MIACIN G Amikacin (sulfate) - 500mg/2ml 500mg/2ml Injectable solution 2,015,764 L.L
J01DH02 MERONEM B Meropenem (trihydrate) - 500mg 500mg Injectable powder for solution 10,398,061 L.L
J01DH02 MERONEM B Meropenem (trihydrate) - 1g 1g Injectable powder for solution 10,398,061 L.L
J01DH02 MEROLIN G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 2,311,146 L.L
J01DH02 MEROPENEM LABATEC G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 7,278,513 L.L
J01DH02 MEROPENEM MEDIS G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 6,443,725 L.L
J01DH02 MEROPENEM PANPHARMA G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 7,278,513 L.L
J01DH02 MEROPENEM/ ANFARM G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 6,443,725 L.L
J01DH02 MEROZAN G Meropenem - 1g 1g Injectable powder for solution 6,443,725 L.L
J01DH02 MIRAN G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 819,744 L.L
J01DD15 MINOCET G Cefdinir - 300mg 300mg Capsule 1,407,003 L.L
J01DD08 MAGNACEF G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 349,399 L.L
J01DD08 MAGNACEF G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 700,142 L.L
J01DD08 MUREX G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 528,130 L.L
J01DD08 MUREX 200 G Cefixime - 200mg 200mg Capsule 430,030 L.L
J01DD08 MAGNACEF 400 G Cefixime - 400mg 400mg Capsule 1,307,559 L.L
J01DD08 MUREX G Cefixime - 400mg 400mg Capsule 679,984 L.L
J01DD04 MEDAXONUM G Ceftriaxone (disodium) (Vial) - 500mg, Lidocaine (ampoule) - 500mg Injectable powder for solution+diluent 307,740 L.L
    5
    ...
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025